Correlation Between Molecular Partners and EPIRUS Biopharmaceutica

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and EPIRUS Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and EPIRUS Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and EPIRUS Biopharmaceuticals, you can compare the effects of market volatilities on Molecular Partners and EPIRUS Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of EPIRUS Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and EPIRUS Biopharmaceutica.

Diversification Opportunities for Molecular Partners and EPIRUS Biopharmaceutica

0.0

Correlation Coefficient

Molecular Partners  EPIRUS Biopharmaceutica

Pay attention - limited upside

The 3 months correlation between Molecular and EPIRUS is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and EPIRUS Biopharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on EPIRUS Biopharmaceuticals and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with EPIRUS Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of EPIRUS Biopharmaceuticals has no effect on the direction of Molecular Partners i.e., Molecular Partners and EPIRUS Biopharmaceutica go up and down completely randomly.

Pair Corralation between Molecular Partners and EPIRUS Biopharmaceutica

If you would invest  521.00  in Molecular Partners AG on September 14, 2024 and sell it today you would earn a total of  34.00  from holding Molecular Partners AG or generate 6.53% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	1.59%
Values	Daily Returns

Molecular Partners AG  vs.  EPIRUS Biopharmaceuticals

Molecular Partners

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point.

EPIRUS Biopharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days EPIRUS Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, EPIRUS Biopharmaceutica is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Pair Trading with Molecular Partners and EPIRUS Biopharmaceutica

The main advantage of trading using opposite Molecular Partners and EPIRUS Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, EPIRUS Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EPIRUS Biopharmaceutica will offset losses from the drop in EPIRUS Biopharmaceutica's long position.

The idea behind Molecular Partners AG and EPIRUS Biopharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.